1. Kawata, AK, Shah, N, Poon, JL, et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache 2021; 61: 438–454.
Google Scholar | Crossref | Medline2. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59: 1–18.
Google Scholar3. Steiner, TJ, Jensen, R, Katsarava, Z, et al. Aids to management of headache disorders in primary care (2nd edition): On behalf of the European Headache Federation and Lifting The Burden: The global campaign against headache. J Headache Pain 2019; 20: 57.
Google Scholar | Crossref | Medline4. Silberstein, S, Lipton, R, Dodick, D, et al. Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49: 1153–1162.
Google Scholar | Crossref | Medline | ISI5. Brandes, JL, Saper, JR, Diamond, M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004; 291: 965–973.
Google Scholar | Crossref | Medline | ISI6. Diener, HC, Bussone, G, Van Oene, JC, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814–823.
Google Scholar | SAGE Journals | ISI7. Diener, HC, Tfelt-Hansen, P, Dahlöf, C, et al. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. Neurology 2004; 251: 943–950.
Google Scholar8. Dodick, DW, Ashina, M, Brandes, JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38: 1026–1037.
Google Scholar | SAGE Journals | ISI9. Edvinsson, L, Haanes, KA, Warfvinge, K, et al. CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 2018; 14: 338–350.
Google Scholar | Crossref | Medline10. Sacco, S, Bendtsen, L, Ashina, M, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 2019; 20: 6.
Google Scholar | Crossref | Medline11. Headache Classification Committee of the International Headache Society . The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.
Google Scholar12. Food and Drug Administration: Topamax®, 2012, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf (2012, accessed January 2021).
Google Scholar13. European Medicines Agency: Topamax®, 2009 , https://www.ema.europa.eu/en/documents/referral/topamax-article-30-referral-annex-i-ii-iii_en.pdf (2009, accessed January 2021).
Google Scholar14. Diener, HC, Tassorelli, C, Dodick, DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 2020; 40: 1026–1044.
Google Scholar | SAGE Journals | ISI15. Goadsby, PJ, Reuter, U, Hallström, Y, et al. A controlled trial of erenumab for episodic migraine. New Eng J Med 2017; 377: 2123–2132.
Google Scholar | Crossref | Medline16. Saris-Baglama, RN, Dewey, CJ, Chisholm, GB, et al. QualityMetric health outcomes™ scoring software 4.0. Lincoln, RI: QualityMetric Incorporated, 2010, p.138.
Google Scholar17. Yang, M, Rendas-Baum, R, Varon, SF, et al. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 2011; 31: 357–367.
Google Scholar | SAGE Journals | ISI18. Bussone, G, Diener, HC, Pfeil, J, et al. Topiramate 100 mg/day in migraine prevention: A pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005; 59: 961–968.
Google Scholar | Crossref | Medline | ISI19. Bayliss M, Batenhorst A. The HIT-6TM: a user’s guide. USA: QualityMetric, Inc, Lincoln, RI, 2002.
Google Scholar20. Reuter, U, Goadsby, PJ, Lanteri-Minet, M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392: 2280–2287.
Google Scholar | Crossref | Medline21. Tepper, S, Ashina, M, Reuter, U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 425–434.
Google Scholar | Crossref | Medline22. Silberstein, SD, Loder, E, Forde, G, et al. The impact of migraine on daily activities: Effect of topiramate compared with placebo. Curr Med Res Opin 2006; 22: 1021–1029.
Google Scholar | Crossref | Medline | ISI23. Woolley, JM, Bonafede, MM, Maiese, BA, et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 2017; 57: 1399–1408.
Google Scholar | Crossref | Medline24. Linde, M, Mulleners, WM, Chronicle, EP, et al . Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; 2013: Cd010610.
Google Scholar25. Silberstein, SD. Topiramate in migraine prevention: A 2016 perspective. Headache 2017; 57: 165–178.
Google Scholar | Crossref | Medline26. Mitsikostas, DD, Mantonakis, LI, Chalarakis, NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011; 31: 550–561.
Google Scholar | SAGE Journals | ISI